Clinical study
Lipid metabolism and apolipoprotein E phenotypes in patients with xanthelasma

https://doi.org/10.1016/S0002-9343(99)80224-1Get rights and content

First page preview

First page preview
Click to open first page preview

References (31)

  • JA Gómez et al.

    Dyslipoproteinemia in patients with xanthelasma

    Arch Dermatol

    (1989)
  • MC Bates et al.

    Xanthelasma: clinical indicator of decreased levels of high-density lipoprotein cholesterol

    South Med J

    (1989)
  • X Pintó et al.

    Dyslipoproteinemia in patients with xanthelasma

    Arch Dermatol

    (1989)
  • FJ Pedace et al.

    Xanthelasma palpebrarum

    JAMA

    (1965)
  • JB Vacca et al.

    Clinical observations regarding xanthelasma

    Ann Intern Med

    (1959)
  • Cited by (46)

    • Serum lipids and risk of atherosclerosis in xanthelasma palpebrarum: A systematic review and meta-analysis

      2020, Journal of the American Academy of Dermatology
      Citation Excerpt :

      In addition to dyslipidemia, hypertension and diabetes mellitus are both well-established risk factors of CVDs.34 Four studies included in our final meta-analysis also showed the prevalence of hypertension and diabetes mellitus in the patients with XP and in controls, and the prevalence of hypertension and diabetes mellitus in both groups was not significantly different in each study.13,17,18,22 Furthermore, we also found no significant difference in a comparison of prevalence of hypertension (P = .086) and diabetes mellitus (P = .704) when we used pooled analysis between the patients with XP and controls.

    • Stable angina pectoris

      2017, Coronary Artery Disease: From Biology to Clinical Practice
    • Visible aging signs as risk markers for ischemic heart disease: Epidemiology, pathogenesis and clinical implications

      2016, Ageing Research Reviews
      Citation Excerpt :

      Roles of apolipoproteins have also been suggested as an explanation for the increased risk of ischemic heart disease. Some studies have suggested a role for decreased levels of apolipoprotein A1 (Pandhi et al., 2012), increased levels of apolipoprotein B (Douste-Blazy et al., 1982; Pandhi et al., 2012; Ribera et al., 1995; Tursen et al., 2006) and/or increased levels of apolipoprotein E (Douste-Blazy et al., 1982) in the association between xanthelasmata and ischemic heart disease in normolipidemic individuals. Although we observe decreased levels of apolipoprotein A1 and increased levels of apolipoprotein B in individuals with xanthelasmata in the Copenhagen City Heart Study (Fig. 5), this reflects the corresponding changes in HDL cholesterol and LDL cholesterol levels.

    View all citing articles on Scopus
    View full text